A novel series of 6-chlorotacrine-scutellarin hybrids was designed, synthesized and the biological activity as potential anti-Alzheimer's agents was assessed. Their inhibitory activity towards human acetylcholinesterase (hAChE) and human butyrylcholinesterase (hBChE), antioxidant activity, ability to cross the blood-brain barrier (BBB) and hepatotoxic profile were evaluated in vitro. Among these compounds, hybrid K1383, bearing two methylene tether between two basic scaffolds, was found to be very potent hAChE inhibitor (IC50 = 1.63 nM). Unfortunately, none of the hybrids displayed any antioxidant activity (EC50 ≥ 500 μM). Preliminary data also suggests a comparable hepatotoxic profile with 6-Cl-THA (established on a HepG2 cell line). Kinetic studies performed on hAChE with the most active compound in the study, K1383, pointed out to a mixed, non-competitive enzyme inhibition. These findings were further corroborated by docking studies.

Biomedical Research Centre University Hospital Hradec Kralove Sokolska 581 500 05 Hradec Kralove Czech Republic

Department of Toxicology and Military Pharmacy Faculty of Military Health Sciences Trebesska 1575 500 01 Hradec Kralove Czech Republic

National Institute of Mental Health Topolova 748 250 67 Klecany Czech Republic

Zobrazit více v PubMed

Sloane P.D., Zimmerman S., Suchindran C., Reed P., Wang L., Boustani M., Sudha S. The public health impact of Alzheimer’s disease, 2000–2050: Potential implication of treatment advances. Annu. Rev. Public Health. 2002;23:213–231. doi: 10.1146/annurev.publhealth.23.100901.140525. PubMed DOI

Alzheimer’s Association Alzheimer’s disease facts and figures. Alzheimer’s Dement. J. Alzheimer’s Assoc. 2016;12:459–509. PubMed

Hippius H., Neundörfer G. The discovery of Alzheimer’s disease. Dialogues Clin. Neurosci. 2003;5:101–108. PubMed PMC

E Mintzer J., F Mirski D., S Hoernig K. Behavioral and psychological signs and symptoms of dementia: A practicing psychiatrist’s viewpoint. Dialogues Clin. Neurosci. 2000;2:139–155. PubMed PMC

Spilovska K., Zemek F., Korabecny J., Nepovimova E., Soukup O., Windisch M., Kuca K. Adamantane—A Lead Structure for Drugs in Clinical Practice. Curr. Med. Chem. 2016;23:3245–3266. doi: 10.2174/0929867323666160525114026. PubMed DOI

Zemek F., Drtinova L., Nepovimova E., Sepsova V., Korabecny J., Klimes J., Kuca K. Outcomes of Alzheimer’s disease therapy with acetylcholinesterase inhibitors and memantine. Expert Opin. Drug Saf. 2014;13:759–774. doi: 10.1517/14740338.2014.914168. PubMed DOI

Spilovska K., Korabecny J., Nepovimova E., Dolezal R., Mezeiova E., Soukup O., Kuca K. Multitarget Tacrine Hybrids with Neuroprotective Properties to Confront Alzheimer’s Disease. Curr. Top. Med. Chem. 2017;17:1006–1026. doi: 10.2174/1568026605666160927152728. PubMed DOI

Geldenhuys W.J., Darvesh A.S. Pharmacotherapy of Alzheimer’s disease: Current and future trends. Expert Rev. Neurother. 2015;15:3–5. doi: 10.1586/14737175.2015.990884. PubMed DOI

Cavalli A., Bolognesi M.L., Minarini A., Rosini M., Tumiatti V., Recanatini M., Melchiorre C. Multi-target-directed ligands to combat neurodegenerative diseases. J. Med. Chem. 2008;51:347–372. doi: 10.1021/jm7009364. PubMed DOI

Prati F., Cavalli A., Bolognesi M.L. Navigating the Chemical Space of Multitarget-Directed Ligands: From Hybrids to Fragments in Alzheimer’s Disease. Molecules (Basel Switzerland) 2016;21:466. doi: 10.3390/molecules21040466. PubMed DOI PMC

Bajda M., Guzior N., Ignasik M., Malawska B. Multi-target-directed ligands in Alzheimer’s disease treatment. Curr. Med. Chem. 2011;18:4949–4975. doi: 10.2174/092986711797535245. PubMed DOI

Guzior N., Wieckowska A., Panek D., Malawska B. Recent development of multifunctional agents as potential drug candidates for the treatment of Alzheimer’s disease. Curr. Med. Chem. 2015;22:373–404. doi: 10.2174/0929867321666141106122628. PubMed DOI PMC

Carreiras M.C., Mendes E., Perry M.J., Francisco A.P., Marco-Contelles J. The multifactorial nature of Alzheimer’s disease for developing potential therapeutics. Curr. Top. Med. Chem. 2013;13:1745–1770. doi: 10.2174/15680266113139990135. PubMed DOI

Bolognesi M.L., Cavalli A., Valgimigli L., Bartolini M., Rosini M., Andrisano V., Recanatini M., Melchiorre C. Multi-target-directed drug design strategy: From a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer’s disease. J. Med. Chem. 2007;50:6446–6449. doi: 10.1021/jm701225u. PubMed DOI

Chen Z., Digiacomo M., Tu Y., Gu Q., Wang S., Yang X., Chu J., Chen Q., Han Y., Chen J., et al. Discovery of novel rivastigmine-hydroxycinnamic acid hybrids as multi-targeted agents for Alzheimer’s disease. Eur. J. Med. Chem. 2017;125:784–792. doi: 10.1016/j.ejmech.2016.09.052. PubMed DOI

Zhu D., Chen M., Li M., Luo B., Zhao Y., Huang P., Xue F., Rapposelli S., Pi R., Wen S. Discovery of novel N-substituted carbazoles as neuroprotective agents with potent anti-oxidative activity. Eur. J. Med. Chem. 2013;68:81–88. doi: 10.1016/j.ejmech.2013.07.029. PubMed DOI

Agis-Torres A., Sölhuber M., Fernandez M., Sanchez-Montero J.M. Multi-Target-Directed Ligands and other Therapeutic Strategies in the Search of a Real Solution for Alzheimer’s Disease. Curr. Neuropharmacol. 2014;12:2–36. doi: 10.2174/1570159X113116660047. PubMed DOI PMC

Recanatini M., Cavalli A., Belluti F., Piazzi L., Rampa A., Bisi A., Gobbi S., Valenti P., Andrisano V., Bartolini M., et al. SAR of 9-amino-1,2,3,4-tetrahydroacridine-based acetylcholinesterase inhibitors: Synthesis, enzyme inhibitory activity, QSAR, and structure-based CoMFA of tacrine analogues. J. Med. Chem. 2000;43:2007–2018. doi: 10.1021/jm990971t. PubMed DOI

Rodríguez-Franco M.I., Fernández-Bachiller M.I., Pérez C., Hernández-Ledesma B., Bartolomé B. Novel tacrine-melatonin hybrids as dual-acting drugs for Alzheimer disease, with improved acetylcholinesterase inhibitory and antioxidant properties. J. Med. Chem. 2006;49:459–462. doi: 10.1021/jm050746d. PubMed DOI

Fernández-Bachiller M.I., Pérez C., Campillo N.E., Páez J.A., González-Muñoz G.C., Usán P., García-Palomero E., López M.G., Villarroya M., García A.G., et al. Tacrine-melatonin hybrids as multifunctional agents for Alzheimer’s disease, with cholinergic, antioxidant, and neuroprotective properties. ChemMedChem. 2009;4:828–841. doi: 10.1002/cmdc.200800414. PubMed DOI

Nepovimova E., Uliassi E., Korabecny J., Peña-Altamira L.E., Samez S., Pesaresi A., Garcia G.E., Bartolini M., Andrisano V., Bergamini C., et al. Multitarget drug design strategy: Quinone-tacrine hybrids designed to block amyloid-β aggregation and to exert anticholinesterase and antioxidant effects. J. Med. Chem. 2014;57:8576–8589. doi: 10.1021/jm5010804. PubMed DOI

Chao X., He X., Yang Y., Zhou X., Jin M., Liu S., Cheng Z., Liu P., Wang Y., Yu J., et al. Design, synthesis and pharmacological evaluation of novel tacrine-caffeic acid hybrids as multi-targeted compounds against Alzheimer’s disease. Bioorg. Med. Chem. Lett. 2012;22:6498–6502. doi: 10.1016/j.bmcl.2012.08.036. PubMed DOI

Nepovimova E., Korabecny J., Dolezal R., Babkova K., Ondrejicek A., Jun D., Sepsova V., Horova A., Hrabinova M., Soukup O., et al. Tacrine-Trolox Hybrids: A Novel Class of Centrally Active, Nonhepatotoxic Multi-Target-Directed Ligands Exerting Anticholinesterase and Antioxidant Activities with Low In Vivo Toxicity. J. Med. Chem. 2015;58:8985–9003. doi: 10.1021/acs.jmedchem.5b01325. PubMed DOI

Digiacomo M., Chen Z., Wang S., Lapucci A., Macchia M., Yang X., Chu J., Han Y., Pi R., Rapposelli S. Synthesis and pharmacological evaluation of multifunctional tacrine derivatives against several disease pathways of AD. Bioorg. Med. Chem. Lett. 2015;25:807–810. doi: 10.1016/j.bmcl.2014.12.084. PubMed DOI

Holmquist L., Stuchbury G., Berbaum K., Muscat S., Young S., Hager K., Engel J., Münch G. Lipoic acid as a novel treatment for Alzheimer’s disease and related dementias. Pharmacol. Ther. 2007;113:154–164. doi: 10.1016/j.pharmthera.2006.07.001. PubMed DOI

Guo L.-L., Guan Z.-Z., Huang Y., Wang Y.-L., Shi J.-S. The neurotoxicity of β-amyloid peptide toward rat brain is associated with enhanced oxidative stress, inflammation and apoptosis, all of which can be attenuated by scutellarin. Exp. Toxicol. Pathol. 2013;65:579–584. doi: 10.1016/j.etp.2012.05.003. PubMed DOI

Ghosh N., Ghosh R., Bhat Z.A., Mandal V., Bachar S.C., Nima N.D., Sunday O.O., Mandal S.C. Advances in herbal medicine for treatment of ischemic brain injury. Nat. Prod. Commun. 2014;9:1045–1055. PubMed

Hong H., Liu G.-Q. Protection against hydrogen peroxide-induced cytotoxicity in PC12 cells by scutellarin. Life Sci. 2004;74:2959–2973. doi: 10.1016/j.lfs.2003.09.074. PubMed DOI

Qian L., Shen M., Tang H., Tang Y., Zhang L., Fu Y., Shi Q., Li N.-G. Synthesis and protective effect of scutellarein on focal cerebral ischemia/reperfusion in rats. Molecules (Basel Switzerland) 2012;17:10667–10674. doi: 10.3390/molecules170910667. PubMed DOI PMC

Chen X., Cui L., Duan X., Ma B., Zhong D. Pharmacokinetics and metabolism of the flavonoid scutellarin in humans after a single oral administration. Drug Metab. Dispos. Biol. Fate Chem. 2006;34:1345–1352. doi: 10.1124/dmd.106.009779. PubMed DOI

Sang Z., Li Y., Qiang X., Xiao G., Liu Q., Tan Z., Deng Y. Multifunctional scutellarin-rivastigmine hybrids with cholinergic, antioxidant, biometal chelating and neuroprotective properties for the treatment of Alzheimer’s disease. Bioorg. Med. Chem. 2015;23:668–680. doi: 10.1016/j.bmc.2015.01.005. PubMed DOI

Lipton S.A. Paradigm shift in neuroprotection by NMDA receptor blockade: Memantine and beyond. Nat. Rev. Drug Discov. 2006;5:160–170. doi: 10.1038/nrd1958. PubMed DOI

Tremblay R., Chakravarthy B., Hewitt K., Tauskela J., Morley P., Atkinson T., Durkin J.P. Transient NMDA receptor inactivation provides long-term protection to cultured cortical neurons from a variety of death signals. J. Neurosci. 2000;20:7183–7192. PubMed PMC

Hu M., Schurdak M.E., Puttfarcken P.S., El Kouhen R., Gopalakrishnan M., Li J. High content screen Microscopy analysis of A beta 1-42-induced neurite outgrowth reduction in rat primary cortical neurons: Neuroprotective effects of alpha 7 neuronal nicotinic acetylcholine receptor ligands. Brain Res. 2007;1151:227–235. doi: 10.1016/j.brainres.2007.03.051. PubMed DOI

Procopio A., Alcaro S., Nardi M., Oliverio M., Ortuso F., Sacchetta P., Pieragostino D., Sindona G. Synthesis, Biological Evaluation, and Molecular Modeling of Oleuropein and Its Semisynthetic Derivatives as Cyclooxygenase Inhibitors. J. Agric. Food Chem. 2009;57:11161–11167. doi: 10.1021/jf9033305. PubMed DOI

Procopio A., Celia C., Nardi M., Oliverio M., Paolino D., Sindona G. Lipophilic Hydroxytyrosol Esters: Fatty Acid Conjugates for Potential Topical Administration. J. Nat. Prod. 2011;74:2377–2381. doi: 10.1021/np200405s. PubMed DOI

Nardi M., Bonacci S., De Luca G., Maiuolo J., Oliverio M., Sindona G., Procopio A. Biomimetic synthesis and antioxidant evaluation of 3,4-DHPEA-EDA [2-(3,4-hydroxyphenyl) ethyl (3S,4E)-4-formyl-3-(2-oxoethyl)hex-4-enoate] Food Chem. 2014;162:89–93. doi: 10.1016/j.foodchem.2014.04.015. PubMed DOI

Sindona G., Caruso A., Cozza A., Fiorentini S., Lorusso B., Marini E., Nardi M., Procopio A., Zicari S. Anti-inflammatory effect of 3,4-DHPEA-EDA [2-(3,4-hydroxyphenyl) ethyl (3S,4E)-4-formyl-3-(2-oxoethyl)hex-4-enoate] on primary human vascular endothelial cells. Curr. Med. Chem. 2012;19:4006–4013. doi: 10.2174/092986712802002536. PubMed DOI

Wang X., Cao J., Wu Y., Wang Q., Xiao J. Flavonoids, Antioxidant Potential, and Acetylcholinesterase Inhibition Activity of the Extracts from the Gametophyte and Archegoniophore of Marchantia polymorpha L. Molecules (Basel Switzerland) 2016;21:360. doi: 10.3390/molecules21030360. PubMed DOI PMC

Spagnuolo C., Napolitano M., Tedesco I., Moccia S., Milito A., Russo G.L. Neuroprotective Role of Natural Polyphenols. Curr. Top. Med. Chem. 2016;16:1943–1950. doi: 10.2174/1568026616666160204122449. PubMed DOI

Russo A., Perri M., Cione E., Di Gioia M.L., Nardi M., Cristina Caroleo M. Biochemical and chemical characterization of Cynara cardunculus L. extract and its potential use as co-adjuvant therapy of chronic myeloid leukemia. J. Ethnopharmacol. 2017;202:184–191. doi: 10.1016/j.jep.2017.03.026. PubMed DOI

Liao S., Deng H., Huang S., Yang J., Wang S., Yin B., Zheng T., Zhang D., Liu J., Gao G., et al. Design, synthesis and evaluation of novel 5,6,7-trimethoxyflavone-6-chlorotacrine hybrids as potential multifunctional agents for the treatment of Alzheimer’s disease. Bioorg. Med. Chem. Lett. 2015;25:1541–1545. doi: 10.1016/j.bmcl.2015.02.015. PubMed DOI

Combes S., Finet J.-P., Siri D. On the optical activity of the 3-aryl-4-hydroxycoumarin isolated from Millettia griffoniana: Molecular modelling and total synthesis. J. Chem. Soc., Perkin Trans. 1. 2002:38–44. doi: 10.1039/B108707J. DOI

Tsou L.K., Lara-Tejero M., RoseFigura J., Zhang Z.J., Wang Y.-C., Yount J.S., Lefebre M., Dossa P.D., Kato J., Guan F., et al. Antibacterial Flavonoids from Medicinal Plants Covalently Inactivate Type III Protein Secretion Substrates. J. Am. Chem. Soc. 2016;138:2209–2218. doi: 10.1021/jacs.5b11575. PubMed DOI PMC

Lambert J.B., Mazzola E.P. Nuclear Magnetic Resonance Spectroscopy: An Introduction to Principles, Applications, and Experimental Methods. Prentice Hall; Saddle River, NJ, USA: 2004.

Hu M.-K., Wu L.-J., Hsiao G., Yen M.-H. Homodimeric tacrine congeners as acetylcholinesterase inhibitors. J. Med. Chem. 2002;45:2277–2282. doi: 10.1021/jm010308g. PubMed DOI

Kónya K., Pajtás D., Kiss-Szikszai A., Patonay T. Buchwald–Hartwig Reactions of Monohaloflavones. Eur. J. Org. Chem. 2015;2015:828–839. doi: 10.1002/ejoc.201403108. PubMed DOI

Ellman G.L., Courtney K.D., Andres V., Feather-Stone R.M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 1961;7:88–95. doi: 10.1016/0006-2952(61)90145-9. PubMed DOI

Pohanka M., Jun D., Kuca K. Improvement of acetylcholinesterase-based assay for organophosphates in way of identification by reactivators. Talanta. 2008;77:451–454. doi: 10.1016/j.talanta.2008.06.007. PubMed DOI

Nordberg A., Ballard C., Bullock R., Darreh-Shori T., Somogyi M. A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer’s disease. Prim. Care Companion CNS Disord. 2013;15 doi: 10.4088/PCC.12r01412. PubMed DOI PMC

Sugimoto H., Ogura H., Arai Y., Limura Y., Yamanishi Y. Research and development of donepezil hydrochloride, a new type of acetylcholinesterase inhibitor. Jpn. J. Pharmacol. 2002;89:7–20. doi: 10.1254/jjp.89.7. PubMed DOI

Bentayeb K., Rubio C., Nerín C. Study of the antioxidant mechanisms of Trolox and eugenol with 2,2’-azobis(2-amidinepropane)dihydrochloride using ultra-high performance liquid chromatography coupled with tandem mass spectrometry. Analyst. 2012;137:459–470. doi: 10.1039/c1an15505a. PubMed DOI

Foti M.C. Antioxidant properties of phenols. J. Pharm. Pharmacol. 2007;59:1673–1685. doi: 10.1211/jpp.59.12.0010. PubMed DOI

Patocka J., Jun D., Kuca K. Possible role of hydroxylated metabolites of tacrine in drug toxicity and therapy of Alzheimer’s disease. Curr. Drug Metab. 2008;9:332–335. doi: 10.2174/138920008784220619. PubMed DOI

Ou B., Hampsch-Woodill M., Prior R.L. Development and validation of an improved oxygen radical absorbance capacity assay using fluorescein as the fluorescent probe. J. Agric. Food Chem. 2001;49:4619–4626. doi: 10.1021/jf010586o. PubMed DOI

Mosmann T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J. Immunol. Methods. 1983;65:55–63. doi: 10.1016/0022-1759(83)90303-4. PubMed DOI

Summers W.K., Koehler A.L., Marsh G.M., Tachiki K., Kling A. Long-term hepatotoxicity of tacrine. Lancet. 1989;1:729. doi: 10.1016/S0140-6736(89)92246-0. PubMed DOI

Di L., Kerns E.H., Fan K., McConnell O.J., Carter G.T. High throughput artificial membrane permeability assay for blood-brain barrier. Eur. J. Med. Chem. 2003;38:223–232. doi: 10.1016/S0223-5234(03)00012-6. PubMed DOI

Lemes L.F.N., de Andrade Ramos G., de Oliveira A.S., da Silva F.M.R., de Castro Couto G., da Silva Boni M., Guimarães M.J.R., Souza I.N.O., Bartolini M., Andrisano V., et al. Cardanol-derived AChE inhibitors: Towards the development of dual binding derivatives for Alzheimer’s disease. Eur. J. Med. Chem. 2016;108:687–700. doi: 10.1016/j.ejmech.2015.12.024. PubMed DOI

Saxena A., Redman A.M., Jiang X., Lockridge O., Doctor B.P. Differences in active site gorge dimensions of cholinesterases revealed by binding of inhibitors to human butyrylcholinesterase. Biochemistry. 1997;36:14642–14651. doi: 10.1021/bi971425+. PubMed DOI

Pang Y.P., Quiram P., Jelacic T., Hong F., Brimijoin S. Highly potent, selective, and low cost bis-tetrahydroaminacrine inhibitors of acetylcholinesterase. Steps toward novel drugs for treating Alzheimer’s disease. J. Biol. Chem. 1996;271:23646–23649. PubMed

Nachon F., Ehret-Sabatier L., Loew D., Colas C., van Dorsselaer A., Goeldner M. Trp82 and Tyr332 are involved in two quaternary ammonium binding domains of human butyrylcholinesterase as revealed by photoaffinity labeling with [3H]DDF. Biochemistry. 1998;37:10507–10513. doi: 10.1021/bi980536l. PubMed DOI

Cheung J., Rudolph M.J., Burshteyn F., Cassidy M.S., Gary E.N., Love J., Franklin M.C., Height J.J. Structures of human acetylcholinesterase in complex with pharmacologically important ligands. J. Med. Chem. 2012;55:10282–10286. doi: 10.1021/jm300871x. PubMed DOI

Nachon F., Carletti E., Ronco C., Trovaslet M., Nicolet Y., Jean L., Renard P.-Y. Crystal structures of human cholinesterases in complex with huprine W and tacrine: Elements of specificity for anti-Alzheimer’s drugs targeting acetyl- and butyryl-cholinesterase. Biochem. J. 2013;453:393–399. doi: 10.1042/BJ20130013. PubMed DOI

Ceschi M.A., da Costa J.S., Lopes J.P.B., Câmara V.S., Campo L.F., Borges A.C.D.A., Gonçalves C.A.S., de Souza D.F., Konrath E.L., Karl A.L.M., et al. Novel series of tacrine-tianeptine hybrids: Synthesis, cholinesterase inhibitory activity, S100B secretion and a molecular modeling approach. Eur. J. Med. Chem. 2016;121:758–772. doi: 10.1016/j.ejmech.2016.06.025. PubMed DOI

Spilovska K., Korabecny J., Kral J., Horova A., Musilek K., Soukup O., Drtinova L., Gazova Z., Siposova K., Kuca K. 7-Methoxytacrine-adamantylamine heterodimers as cholinesterase inhibitors in Alzheimer’s disease treatment--synthesis, biological evaluation and molecular modeling studies. Molecules (Basel Switzerland) 2013;18:2397–2418. doi: 10.3390/molecules18022397. PubMed DOI PMC

Spilovska K., Korabecny J., Horova A., Musilek K., Nepovimova E., Drtinova L., Gazova Z., Siposova K., Dolezal R., Jun D., et al. Design, synthesis and in vitro testing of 7-methoxytacrine-amantadine analogues: A novel cholinesterase inhibitors for the treatment of Alzheimer’s disease. Med. Chem. Res. 2015;24:2645–2655. doi: 10.1007/s00044-015-1316-x. DOI

Korabecny J., Andrs M., Nepovimova E., Dolezal R., Babkova K., Horova A., Malinak D., Mezeiova E., Gorecki L., Sepsova V., et al. 7-Methoxytacrine-p-Anisidine Hybrids as Novel Dual Binding Site Acetylcholinesterase Inhibitors for Alzheimer’s Disease Treatment. Molecules. 2015;20:22084–22101. doi: 10.3390/molecules201219836. PubMed DOI PMC

Misik J., Korabecny J., Nepovimova E., Cabelova P., Kassa J. The effects of novel 7-MEOTA-donepezil like hybrids and N-alkylated tacrine analogues in the treatment of quinuclidinyl benzilate-induced behavioural deficits in rats performing the multiple T-maze test. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub. 2015;159:547–553. doi: 10.5507/bp.2015.006. PubMed DOI

Korabecny J., Dolezal R., Cabelova P., Horova A., Hruba E., Ricny J., Sedlacek L., Nepovimova E., Spilovska K., Andrs M., et al. 7-MEOTA–donepezil like compounds as cholinesterase inhibitors: Synthesis, pharmacological evaluation, molecular modeling and QSAR studies. Eur. J. Med. Chem. 2014;82:426–438. doi: 10.1016/j.ejmech.2014.05.066. PubMed DOI

Heo H., Cho H.-Y., Hong B., Kim H.-K., Kim E., Kim B.-G., Shin D.-H. Protective effect of 4′,5-dihydroxy-3′,6,7-trimethoxyflavone from Artemisia asiatica against Aβ-induced oxidative stress in PC12 cells. Amyloid. 2001;8:194–201. doi: 10.3109/13506120109007362. PubMed DOI

Carlier P.R., Chow E.S., Han Y., Liu J., El Yazal J., Pang Y.P. Heterodimeric tacrine-based acetylcholinesterase inhibitors: investigating ligand-peripheral site interactions. J. Med. Chem. 1999;42:4225–4231. doi: 10.1021/jm990224w. PubMed DOI

Ariel N., Ordentlich A., Barak D., Bino T., Velan B., Shafferman A. The “aromatic patch” of three proximal residues in the human acetylcholinesterase active centre allows for versatile interaction modes with inhibitors. Biochem. J. 1998;335:95–102. doi: 10.1042/bj3350095. PubMed DOI PMC

Fang L., Pan Y., Muzyka J.L., Zhan C.-G. Active site gating and substrate specificity of butyrylcholinesterase and acetylcholinesterase: Insights from molecular dynamics simulations. J. Phys. Chem. B. 2011;115:8797–8805. doi: 10.1021/jp112030p. PubMed DOI PMC

Pan Y., Chen Y., Li Q., Yu X., Wang J., Zheng J. The synthesis and evaluation of novel hydroxyl substituted chalcone analogs with in vitro anti-free radicals pharmacological activity and in vivo anti-oxidation activity in a free radical-injury Alzheimer’s model. Molecules (Basel Switzerland) 2013;18:1693–1703. doi: 10.3390/molecules18021693. PubMed DOI PMC

Sugano K., Hamada H., Machida M., Ushio H. High throughput prediction of oral absorption: improvement of the composition of the lipid solution used in parallel artificial membrane permeation assay. J. Biomol. Screen. 2001;6:189–196. doi: 10.1089/108705701300362728. PubMed DOI

Wohnsland F., Faller B. High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes. J. Med. Chem. 2001;44:923–930. doi: 10.1021/jm001020e. PubMed DOI

Pettersen E.F., Goddard T.D., Huang C.C., Couch G.S., Greenblatt D.M., Meng E.C., Ferrin T.E. UCSF Chimera—A visualization system for exploratory research and analysis. J. Comput. Chem. 2004;25:1605–1612. doi: 10.1002/jcc.20084. PubMed DOI

Morris G.M., Huey R., Lindstrom W., Sanner M.F., Belew R.K., Goodsell D.S., Olson A.J. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J. Comput. Chem. 2009;30:2785–2791. doi: 10.1002/jcc.21256. PubMed DOI PMC

Lee Kwang S., Park Kyun M., Yi J., Won Cho D., Sup Ra C., Musilek K., Horova A., Korabecny J., Dolezal R., Jun D., et al. Preparation of 7-methoxy tacrine dimer analogs and their in vitro/in silico evaluation as potential choliensterase inhibitors. Bull. Korean Chem. Soc. 2015 doi: 10.1002/bkcs.10317. DOI

Dolezal R., Korabecny J., Malinak D., Honegr J., Musilek K., Kuca K. Ligand-based 3D QSAR analysis of reactivation potency of mono- and bis-pyridinium aldoximes toward VX-inhibited rat acetylcholinesterase. J. Mol. Graph. Model. 2015;56:113–129. doi: 10.1016/j.jmgm.2014.11.010. PubMed DOI

Soukup O., Jun D., Zdarova-Karasova J., Patocka J., Musilek K., Korabecny J., Krusek J., Kaniakova M., Sepsova V., Mandikova J., et al. A resurrection of 7-MEOTA: A comparison with tacrine. Curr. Alzheimer Res. 2013;10:893–906. doi: 10.2174/1567205011310080011. PubMed DOI

Korabecny J., Musilek K., Holas O., Nepovimova E., Jun D., Zemek F., Opletalova V., Patocka J., Dohnal V., Nachon F., et al. Synthesis and in vitro evaluation of N-(Bromobut-3-en-2-yl)-7-methoxy-1,2,3,4-tetrahydroacridin-9-amine as a cholinesterase inhibitor with regard to Alzheimer’s disease treatment. Molecules (Basel Switzerland) 2010;15:8804–8812. doi: 10.3390/molecules15128804. PubMed DOI PMC

O’Boyle N.M., Banck M., James C.A., Morley C., Vandermeersch T., Hutchison G.R. Open Babel: An open chemical toolbox. J. Cheminform. 2011;3:33. doi: 10.1186/1758-2946-3-33. PubMed DOI PMC

Trott O., Olson A.J. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 2010;31:455–461. doi: 10.1002/jcc.21334. PubMed DOI PMC

Privileged multi-target directed propargyl-tacrines combining cholinesterase and monoamine oxidase inhibition activities

Pursuing the Complexity of Alzheimer's Disease: Discovery of Fluoren-9-Amines as Selective Butyrylcholinesterase Inhibitors and N-Methyl-d-Aspartate Receptor Antagonists

Development of 2-Methoxyhuprine as Novel Lead for Alzheimer's Disease Therapy